Phaseline

Targets › PKLR

PKLR (Pyruvate kinase PKLR): drug programs, companies and trials

4 programs from 4 companies in 19 trials: 12 Phase 3, 5 Phase 2, 2 Phase 1; Hematology; next expected readout Mar 2027.

Pyruvate kinase that catalyzes the conversion of phosphoenolpyruvate to pyruvate with the synthesis of ATP, and which plays a key role in glycolysis. Also produces the side product 2-phospholactate which can inhibit fructose-2,6-bisphosphate production. 2-phospholactate can be dephosphorylated by PGP which prevents the inhibition of fructose-2,6-bisphosphate production and allows glycolysis to occur. (UniProt, P30613)

Open in Phaseline: the race on PKLR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Forma TherapeuticsEtavopivat
Pyruvate kinase isozymes R/L activator
PKLRPhase 3Sickle Cell DiseaseMar 2027
Novo NordiskEtavopivat
Pyruvate kinase isozymes R/L activator
PKLRPhase 3Sickle Cell DiseaseAug 2027
Agios PharmaceuticalsMitapivat
Pyruvate kinase isozymes R/L activator
PKLRPhase 3Non-Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Alpha-Thalassemia; Pediatric Pyruvate Kinase Deficiency; Sickle Cell Disease …Dec 2028
ScinnoHub PharmaceuticalSNH-119014
Pyruvate kinase red blood cell isozyme (PKR) agonist
PKLRPhase 1Hemoglobinopathy–

Conditions

Sickle Cell Disease (10) Non-Transfusion-dependent Alpha-Thalassemia (2) Transfusion-dependent Alpha-Thalassemia (2) Pediatric Pyruvate Kinase Deficiency (2) Thalassemia (1) Anemia (1) Hemoglobinopathy (1)

Modalities

small molecule (4)

Companies

Forma Therapeutics (1) Agios Pharmaceuticals (1) ScinnoHub Pharmaceutical (1) Novo Nordisk (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.